Reporting of melanoma cell densities in the sentinel node refines outcome prediction

Ulmer, Anja; Pfefferle, Vanessa; Walter, Vincent; Granai, Massimo; Keim, Ulrike; Fend, Falko; Sulyok, Mihály; Bösmüller, Hans

doi:10.1016/j.ejca.2022.06.054

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sentinel nodes are examined by serial sectioning followed by methodical pathological analysis, including immunohistochemistry and melanoma-specific stains [ 4 , 5 , 15 , 16 , 36 , 86 , 97 , 98 , 99 , 100 ]. Fewer nodes are examined in greater detail, increasing the detection of smaller metastasis [ 97 , 98 ].…”

Section: Management Of Positive Sentinel Nodesmentioning

confidence: 99%

“…Moreover, despite evidence that a low volume of tumour in a sentinel node decreases the probability of metastatic disease in nonsentinel nodes, even minimal metastasis to sentinel nodes increases the risk of locoregional recurrence and death relative to patients with negative sentinel nodes [ 100 ]. Bremmer et al reviewed a database of 1250 consecutive patients who underwent SLNB for primary cutaneous melanoma [ 97 ].…”

Section: Management Of Positive Sentinel Nodesmentioning

confidence: 99%

See 1 more Smart Citation

The Evolution of the Sentinel Node Biopsy in Melanoma

Allard-Coutu

Dobson

Schmitz

et al. 2023

Life

View full text Add to dashboard Cite

The growing repertoire of approved immune-checkpoint inhibitors and targeted therapy has revolutionized the adjuvant treatment of melanoma. While the treatment of primary cutaneous melanoma remains wide local excision (WLE), the management of regional lymph nodes continues to evolve in light of practice-changing clinical trials and dramatically improved adjuvant therapy. With large multicenter studies reporting no benefit in overall survival for completion lymph node dissection (CLND) after a positive sentinel node biopsy (SLNB), controversy remains regarding patient selection and clinical decision-making. This review explores the evolution of the SLNB in cutaneous melanoma in the context of a rapidly changing adjuvant treatment landscape, summarizing the key clinical trials which shaped current practice guidelines.

show abstract